The Australian government is investing AU$1.89 billion (US$1.25 billion) in what it is calling a “once-in-a generation transformation” of health and medical research in Australia with $1.4 billion tagged for new research for the Medical Research Future Fund.
China and U.S. biotech Jacobio Pharmaceuticals Group Co. Ltd.’s shares (HKEX:1167) rose nearly 20% after it filed an NDA in China on May 6 for its independently developed KRAS G12C inhibitor, glecirasib (JAB-21822), to treat lung cancer.
Appicine Therapeutics (HK) Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety coupled to a Bcl-2-like protein 1 (Bcl-xL; Bcl-X; BCL2L1)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
Researchers from Gempharmatech Co. Ltd. presented a new humanized mouse model for preclinical research into the functionality and therapeutic potential of IL-12.
Bioatla Inc. has received FDA clearance of its IND application for BA-3361, a conditionally active biologic (CAB)-Nectin-4 antibody-drug conjugate (ADC) for the treatment of multiple tumor types.
Researchers from ADC Therapeutics SA presented the discovery and preclinical evaluation of a novel camptothecin-based Claudin-6-specific antibody-drug conjugate (ADC), GB01-VA-PL2202.
Lantern Pharma Inc. has entered into a strategic artificial intelligence (AI)-driven collaboration with Oregon Therapeutics SAS to optimize the development of Oregon’s first-in-class protein disulfide isomerase (PDI) inhibitor drug candidate XCE-853 in novel and targeted cancer indications.
Eisbach Bio GmbH has announced FDA clearance of its IND application for EIS-12656, a first-in-class orally bioavailable and blood-brain barrier-penetrant allosteric inhibitor of ALC1 (CHD1L), a key molecular machine in DNA repair. Enrollment will open in the second quarter in a phase I/II trial in patients with genetically defined advanced solid tumors, including patients progressing under PARP inhibitor treatment.
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, in part due to the immunosuppression surrounding the tumor mediated by regulatory T cells (Tregs), thus preventing effective responses to immune therapy.